{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:59:15Z","timestamp":1785481155262,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor Treating Fields improve survival when started after chemoradiotherapy in newly diagnosed glioblastoma, but the safety and feasibility of initiating treatment before and during radiotherapy remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PriCoTTF is a prospective, open-label, nonrandomized, multicenter phase I\/II trial. Arm A enrolled adults aged 18 to 70 years with newly diagnosed IDH-wildtype glioblastoma or gliosarcoma, Karnofsky Performance Status of at least 60, and planned focal radiotherapy to 60 Gy in 30 fractions. TTFields at 200 kHz were initiated 2 to 4 weeks after surgery and 1 to 2 weeks before radiotherapy. The primary endpoint was protocol-defined treatment-limiting toxicity from TTFields initiation through 4 weeks after radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty evaluable patients comprised the Arm A feasibility cohort. No protocol-defined treatment-limiting toxicities occurred (0 of 20 patients; exact 95% CI, 0.0%-16.8%). Grade 3 or higher adverse events occurred in 12 patients (60%), predominantly hematologic toxicity attributable to chemoradiotherapy; lymphopenia occurred in 6 patients (30%). Median usage through visit 4 was 76.5%, and median time to first attainment of at least 75% daily use was 2 days. Median progression-free survival was 6.9 months (95% CI, 2.7\u201314.0), and median overall survival was 18.0 months (95% CI, 12.1\u201319.9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initiation of TTFields before and during radiotherapy was feasible and was not associated with protocol-defined treatment-limiting toxicity in the Arm A cohort. Because the TLT definition was narrow and efficacy analyses were exploratory and exposure-conditioned, these findings should be interpreted as feasibility data rather than evidence of improved tumor control or survival. The results support randomized evaluation of earlier TTFields integration in newly diagnosed glioblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>German Clinical Trials Register DRKS00016667, registered 26 February 2019.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16613-y","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:03:43Z","timestamp":1785150223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I\/II trial (PriCoTTF)"],"prefix":"10.1186","volume":"26","author":[{"given":"Sied","family":"Kebir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Jekel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Grieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Cappello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kizina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Lazaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laur\u00e8l","family":"Rauschenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Ahmadipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Feldheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pierscianek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Proescholdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Krex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"P\u00f6ttgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"8","key":"16613_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"issue":"Supplement_4","key":"16613_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","volume":"27","author":"M Price","year":"2025","unstructured":"Price M, Ballard CAP, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022. Neuro Oncol. 2025;27(Supplement_4):iv1\u201366. https:\/\/doi.org\/10.1093\/neuonc\/noaf194.","journal-title":"Neuro Oncol"},{"key":"16613_CR3","doi-asserted-by":"publisher","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro Oncol. 2024;26(Supplement_6):vi1\u2013vi85. https:\/\/doi.org\/10.1093\/neuonc\/noae145.","DOI":"10.1093\/neuonc\/noae145"},{"issue":"10","key":"16613_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"issue":"10","key":"16613_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331.","journal-title":"N Engl J Med"},{"issue":"2","key":"16613_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","volume":"95","author":"M Lacroix","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190\u20138. https:\/\/doi.org\/10.3171\/jns.2001.95.2.0190.","journal-title":"J Neurosurg"},{"issue":"10172","key":"16613_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","volume":"393","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(18)31791-4.","journal-title":"Lancet"},{"issue":"23","key":"16613_CR8","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306\u201316. https:\/\/doi.org\/10.1001\/jama.2017.18718.","journal-title":"JAMA"},{"issue":"Suppl 6","key":"16613_CR9","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminoncol.2014.09.010","volume":"41","author":"MM Mrugala","year":"2014","unstructured":"Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, et al. Clinical practice experience with NovoTTF-100A system for glioblastoma: the Patient Registry Dataset (PRiDe). Semin Oncol. 2014;41(Suppl 6):S4\u201313. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.09.010.","journal-title":"Semin Oncol"},{"issue":"9","key":"16613_CR10","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1158\/0008-5472.can-04-0083","volume":"64","author":"ED Kirson","year":"2004","unstructured":"Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288\u201395. https:\/\/doi.org\/10.1158\/0008-5472.can-04-0083.","journal-title":"Cancer Res"},{"key":"16613_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep18046","volume":"5","author":"M Giladi","year":"2015","unstructured":"Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:18046. https:\/\/doi.org\/10.1038\/srep18046.","journal-title":"Sci Rep"},{"issue":"1","key":"16613_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-017-0941-6","volume":"12","author":"M Giladi","year":"2017","unstructured":"Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017;12(1):206. https:\/\/doi.org\/10.1186\/s13014-017-0941-6.","journal-title":"Radiat Oncol"},{"issue":"1","key":"16613_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-018-0976-3","volume":"13","author":"C Straube","year":"2018","unstructured":"Straube C, Oechsner M, Kampfer S, Scharl S, Schmidt-Graf F, Wilkens JJ, et al. Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study. Radiat Oncol. 2018;13(1):31. https:\/\/doi.org\/10.1186\/s13014-018-0976-3.","journal-title":"Radiat Oncol"},{"issue":"1","key":"16613_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.adro.2019.08.005","volume":"5","author":"GC Stachelek","year":"2020","unstructured":"Stachelek GC, Grimm J, Moore J, Huang E, Spoleti N, Redmond KJ, et al. Tumor-treating field arrays do not reduce target volume coverage for glioblastoma radiation therapy. Adv Radiat Oncol. 2020;5(1):62\u20139. https:\/\/doi.org\/10.1016\/j.adro.2019.08.005.","journal-title":"Adv Radiat Oncol"},{"key":"16613_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00411","volume":"10","author":"F Bokstein","year":"2020","unstructured":"Bokstein F, Blumenthal D, Limon D, Harosh CB, Ram Z, Grossman R. Concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: a prospective safety and feasibility study. Front Oncol. 2020;10:411. https:\/\/doi.org\/10.3389\/fonc.2020.00411.","journal-title":"Front Oncol"},{"issue":"6","key":"16613_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1215\/15228517-2009-005","volume":"11","author":"A Pirzkall","year":"2009","unstructured":"Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2009;11(6):842\u201352. https:\/\/doi.org\/10.1215\/15228517-2009-005.","journal-title":"Neuro Oncol"},{"issue":"1","key":"16613_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11060-017-2511-z","volume":"134","author":"JE Villanueva-Meyer","year":"2017","unstructured":"Villanueva-Meyer JE, Han SJ, Cha S, Butowski NA. Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. J Neurooncol. 2017;134(1):213\u20139. https:\/\/doi.org\/10.1007\/s11060-017-2511-z.","journal-title":"J Neurooncol"},{"issue":"5","key":"16613_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/nop\/npac044","volume":"9","author":"RD Kraus","year":"2022","unstructured":"Kraus RD, Weil CR, Frances Su FC, Cannon DM, Burt LM, Mendez JS. Incidence and extent of disease progression on MRI between surgery and initiation of radiotherapy in glioblastoma patients. Neurooncol Pract. 2022;9(5):380\u20139. https:\/\/doi.org\/10.1093\/nop\/npac044.","journal-title":"Neurooncol Pract"},{"issue":"1","key":"16613_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac075","volume":"4","author":"M Waqar","year":"2022","unstructured":"Waqar M, Roncaroli F, Lehrer EJ, Palmer JD, Villanueva-Meyer J, Braunstein S, et al. Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: results from a systematic review and meta-analysis. Neuro-oncol Adv. 2022;4(1):vdac075. https:\/\/doi.org\/10.1093\/noajnl\/vdac075.","journal-title":"Neuro-oncol Adv"},{"issue":"16_suppl","key":"16613_CR20","doi-asserted-by":"publisher","first-page":"TPS2083","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2083","volume":"41","author":"W Shi","year":"2023","unstructured":"Shi W, Roberge D, Kleinberg L, Jeyapalan SA, Goldlust SA, Nagpal S, et al. Phase 3 TRIDENT study (EF-32): tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy\/temozolomide in newly diagnosed glioblastoma. J Clin Oncol. 2023;41(16_suppl):TPS2083\u2013TPS2083. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS2083.","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"16613_CR21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.03.011","volume":"41","author":"ME Lacouture","year":"2014","unstructured":"Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, et al. Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014;41(Suppl 4):S1-14. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.03.011.","journal-title":"Semin Oncol"},{"issue":"2","key":"16613_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","volume":"141","author":"SA Toms","year":"2019","unstructured":"Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467\u201373. https:\/\/doi.org\/10.1007\/s11060-018-03057-z.","journal-title":"J Neurooncol"},{"issue":"11","key":"16613_CR23","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963\u201372. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541.","journal-title":"J Clin Oncol"},{"issue":"16","key":"16613_CR24","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","volume":"17","author":"SA Grossman","year":"2011","unstructured":"Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0774.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"16613_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJB Taphoorn","year":"2018","unstructured":"Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495\u2013504. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5082.","journal-title":"JAMA Oncol"},{"key":"16613_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01045","volume":"10","author":"ME Lacouture","year":"2020","unstructured":"Lacouture ME, Anadkat MJ, Ballo MT, Iwamoto F, Jeyapalan SA, La Rocca RV, et al. Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma. Front Oncol. 2020;10:1045. https:\/\/doi.org\/10.3389\/fonc.2020.01045.","journal-title":"Front Oncol"},{"issue":"5","key":"16613_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jjco\/hyad001","volume":"53","author":"R Nishikawa","year":"2023","unstructured":"Nishikawa R, Yamasaki F, Arakawa Y, Muragaki Y, Narita Y, Tanaka S, et al. Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF system: a prospective post-approval study. Jpn J Clin Oncol. 2023;53(5):371\u20137. https:\/\/doi.org\/10.1093\/jjco\/hyad001.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"16613_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11060-024-04682-7","volume":"169","author":"MM Mrugala","year":"2024","unstructured":"Mrugala MM, Shi W, Iwomoto F, Lukas RV, Palmer JD, Suh JH, et al. Global post\u2011marketing safety surveillance of tumor treating fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022. J Neurooncol. 2011;169(1):25\u201338. . https:\/\/doi.org\/10.1007\/s11060-024-04682-7","journal-title":"J Neurooncol"},{"issue":"3","key":"16613_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11912-021-01157-0","volume":"24","author":"M Waqar","year":"2022","unstructured":"Waqar M, Trifiletti DM, McBain C, O\u2019Connor J, Coope DJ, Akkari L, et al. Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature. Curr Oncol Rep. 2022;24(3):311\u201324. https:\/\/doi.org\/10.1007\/s11912-021-01157-0.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"16613_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-023-04348-w","volume":"164","author":"MT Ballo","year":"2023","unstructured":"Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. J Neurooncol. 2023;164(1):1\u20139. https:\/\/doi.org\/10.1007\/s11060-023-04348-w.","journal-title":"J Neurooncol"},{"key":"16613_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111395","volume":"138","author":"DJ Crompton","year":"2025","unstructured":"Crompton DJ, Kern S, Bogan A, Do B, Vora S, Quinones-Hinojosa A, et al. Tumor treating fields utilization and efficacy for glioblastoma at a large multicenter academic practice. J Clin Neurosci. 2025;138:111395. https:\/\/doi.org\/10.1016\/j.jocn.2025.111395.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"16613_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-025-04946-w","volume":"173","author":"DC Riegel","year":"2025","unstructured":"Riegel DC, Bureau BL, Conlon P, Chavez G, Connelly JM. Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting. J Neurooncol. 2025;173(1):49\u201357. https:\/\/doi.org\/10.1007\/s11060-025-04946-w.","journal-title":"J Neurooncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16613-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:23:00Z","timestamp":1785478980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16613-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16613"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16613-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP E6(R2). The coordinating center ethics committee of the Medizinische Fakultaet der Universitaet Duisburg-Essen approved the trial (vote 18\u20138316-MF; 6 February 2019), and all participating sites obtained local approvals. All patients provided written informed consent, including consent for device log-file collection and de-identified data sharing.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript contains no identifiable individual participant information, images, or videos.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CO has received travel support from Novocure and honoraria from Horizon and Novocure. CO has received a Clinician Scientist stipend from the University Medicine Essen Clinician Scientist Academy (UMEA), funded by the Faculty of Medicine and the Deutsche Forschungsgemeinschaft (DFG), and a research grant from Servier. SK is a fellow of the Else Kroener-Fresenius Foundation and the Advanced Clinician Scientist Program (UMEA2), funded by the Federal Ministry of Research, Technology and Space (BMFTR) in the framework of the Advanced Clinician Scientist Programme UMEA2; 01EO210. SK received research grants from Novocure and Servier, as well as honoraria and consulting fees from Novocure (institutional). All other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"912"}}